In vitro sensitivity of human anaerobic pathogenic bacteria for tigecycline and comparative antibiotics in Hungary;Humán patogén anaerob baktériumok in vitro érzékenysége tigecyclinre és a komparátor antibiotikumokra Magyarországon Prospektív, többcentrumos vizsgálat

Lege Artis Medicinae

Volumn 19, Issue 10, 2009, Pages 593-601

  Nagy, Erzsébet ^a   Urbán, Edit ^a   Jakab, Gabriella ^b   Szikra, Lenke ^c   Miszti, Cecília ^d   Szabó, Judit ^d  

^a UNIVERSITY OF SZEGED   (Hungary)

^b ANTSZ Laboratóriumi Kft Feiér Meegyei Mikrobiolósiai Laboratórium   (Hungary)

^c Laboratory of Clinical Microbiology   (Hungary)

^d UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Anaerobic bacteria; Antibiotic resistance; In vitro efficiency; Tigecycline

Indexed keywords

EID: 70350442545     PISSN: 08664811     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Olivia ME, Rekha A, Yellin A, et al. A multicentre trial of the efficacy and safety of tigecycline versus imipenem/cilastatin in patients with complicated intra-abdominal infections BMC. Infect Dis 2005;5:88.
2. Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious In the treatment of complicated intra-abdominal infections. Int J Surg 2005;3:35-47. (Pubitemid 41095566)
3. Sacchidanad S, Penn RL, Bmbil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a Phase 3, randomized, double-blind trial. Int Infect Dis 2005;9:251-261
4. Breedt J, Teras J, Gardovskis J, et al. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother 2005;49(11): 4658-4666 (Pubitemid 41552597)
5. Goldstein EJC, Citron DM, Merriam CV, et al. Comarative in vitro susceptibilities of 396 Unusual anaerobic strains to tigecycline and eight other antimicrobial agents. Antimicrob Agents Chemother 2006;50:3507-3513
6. Jacobus NY McDermott LA, Ruthazer R, et al. In vitro activity of tigecyclin against the Bacteroides fragilis group. Antimicrob Agents Chemoter 2004;48:1034-1036 (Pubitemid 38280363)
7. Pertersen PJ, Jacobus NV Weiss WJ, et al. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t butylglycylamido derivative of minocycline (GAR-J36. Antimicrob Agents Chemother 1999;44:738-744
8. Fluit AC, Florijn A, Verhoes J, et al. Presence of tetracycline resistance determinants and susceptibility to tigecycline and minocycline. Antimicrob Agents Chemother 2005;49:1636-1638 (Pubitemid 40463409)
9. ChopraI.Geneticandbiochemicalbasisoftetracyclineresistance. JAntimicrobChemother1986,18(SupplC):51-56(Pubitemid17174047)
10. Bauer G, Berens C, Projan SJ, et al. Comparison of tetracycline and tigecycline binding to ribosomes mapped by dimethylsulophate and drug-directed Fe2+ cleavage of 16S rRNA. J Animicrob Chemother 2004;53:592-599 (Pubitemid 38499772)
11. Yang W, Moore IF, Koteva KP, et al. TetX is a flavin-dependent monooxygenase conferring resistance to tetracycline antibiotics. J Biol Chem 2004;279:52346-52352 (Pubitemid 39656610)
12. Snydman DR, Jacobus NV McDermott LA, et al. National survey on the susceptibility of Bacteroides fragilis group: report and analysis of trends for 1997-2000. Clin Infect Dis 2002;35:S126-34.
13. Hecht DW. Prevalence of antibiotic resistance in anaerobic bacteria: worrisome development. CID 2004;39:92-97
14. Hecht DW. Anaerobes: antibiotic resistance, clinical significance, and the tole of susceptibility testing. Anaerobe 2006;12:115-121 (Pubitemid 43831678)
15. Hedberg M, Nord CE. Antibiotic susceptibilities of Bacteroides fragilis group isolates in Europe. Clin Microbiol Infect 2003;9:475-488 (Pubitemid 36833791)
16. Sóki J, Edwards R, Hedberg M, et al. Examination of cfiA-mediated carbapenem resistance in Bacteroides fragilis from a European antibiotic susceptibility survey. Int J Antimicrob Agents 2006,28: 497-502. (Pubitemid 44794458)
17. Brazier IS, Subbs SI, Duerden BI. Metronidazole resistance among clinical isoltes belonging to the Bacteroides fragilis group: time to be concerned? J Antimicrob Chemother 1999;44:580-581
18. Sóki J, Gal M, Brazier JS, Rotimi, et al. Molecular investigation of genetic elements contributing to metronidazole resistance in Bacteroides strains. J Antimicrob Chemother 2006;57:212-220 (Pubitemid 43160160)
19. Oh H, El Amin N, Devies T, et al. GyrA mutation associated with quinolon resistance in Bacteroides fragilis group strains. Antimicrob Agents Chemother 2001;45:1977-1981 (Pubitemid 32591686)
20. httpZ/www.eucast.org/clinical-breakpoints/
21. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Sixteenth Informational Supplement. CLSI document. M100-S16. Clinical and Laboratory Standards Institute, Wayne, PA., USA, 2006.
22. Pankey GA. Tigecycline. J Antimicrob Chemother 2005;56:470-480
23. Glupczynski Y, Berhin C, Nizet H. Antimicrobial susceptibility of anaerobic bacteria in Belgium as determined by E-test methodology. Eur J Clin Microbiol Infect Dis 2009;28:261-267
24. Wybo I, Piérard D, Verschraegen I, et al. Third Belgian multicentre survey of antibiotic susceptibility of anaerobic bacteria. J Antimicrob Chemother 2007;59:132-139 (Pubitemid 46017916)
25. Katsandri A, Avlamis A, Pantazatou A, et al. In vitro activities of tigecycline against recently isolated Gram-negative anaerobic bacteria in Greece, including metronidazole-resistant strains. Hellenic Study Group for Gram-negative anaerobic bacteria. Diag Microbiol Infect Dis 2006;55:231-236
26. Sotto A, Bouziges N, Jourdan N, et al. In vitro activity of tigecycline against strains isolated from diabetic foot ulcers. Pathol Biol (Paris) 2007;55(8-9):398-406. (Pubitemid 350017721)
27. Konkoly Thege M, Nikolova R. A tigecyclin, egy új glycylcyclin antibiotikum in vitro hatékonyságának vizsgálata Magyarországon. Multicentrics tanulmány. Infektológia és Klinikai Mikrobiológia 2006;14 (3/4):83-91.